BiotechTube

Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mg

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alpha-1 Antitrypsin Deficiency

Conditions

Alpha-1 Antitrypsin Deficiency

Trial Timeline

Apr 1, 2014 → May 1, 2016

NCT ID
NCT02001688

About Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mg

Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mg is a phase 2 stage product being developed by Kamada for Alpha-1 Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02001688. Target conditions include Alpha-1 Antitrypsin Deficiency.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02001688Phase 2Completed

Competing Products

13 competing products in Alpha-1 Antitrypsin Deficiency

See all competitors
ProductCompanyStageHype Score
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) PlaceboNovartisPhase 2
52
VX-668 + PlaceboVertex PharmaceuticalsPhase 1
32
VX-864Vertex PharmaceuticalsPhase 2
51
ALN-AAT02 + Placebo + ALN-AAT02Alnylam PharmaceuticalsPhase 1/2
38
ARC-AAT Injection + DiphenhydramineArrowhead PharmaceuticalsPhase 1
30
ARC-AAT InjectionArrowhead PharmaceuticalsPhase 2
49
Alpha-1 MPGrifolsPhase 3
74
Alpha-1 MPGrifolsPhase 3
74
WVE-006WaVe Life SciencesPhase 1
28
WVE-006WaVe Life SciencesPhase 1/2
36
INBRX-101/rhAAT-FcInhibrx BiosciencesPhase 1
28
KRRO-110Korro BioPhase 1/2
33
Alvelestat (MPH966)Mereo BioPharmaPhase 2
44

Other Products from Kamada

CytogamApproved
77
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three monthsApproved
77
KamRAB - HRIGPhase 3
69
Alpha 1-Antitrypsin + PlaceboPhase 3
69
Active rabies vaccine (US-FDA approved)Phase 2/3
57